StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3073% above fair value
$6.90−0.41 (-5.61%)

Close on Nov 20, 2026Market cap $3.13BP/E –Yield –

Iovance Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Iovance Biotherapeutics's pe ratio was 4.0× on Jul 31, 2013.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2013Jul 31, 20134.0×–

More Iovance Biotherapeutics figures

See a number that looks wrong?